Anecortave Acetate for Treating or Preventing Choroidal Neovascularization

Ophthalmology Clinics of North America

Volumn 19, Issue 3, 2006, Pages 373-380

  Slakter, Jason S ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; AL 4940; ANECORTAVE; BENZOPORPHYRIN DERIVATIVE; GLUCOCORTICOID; OXYGEN; PEGAPTANIB; RANIBIZUMAB;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BACKACHE; CANNULA; CATARACT; CHICK EMBRYO; CHORIOALLANTOIS; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CORNEA LIMBUS; DOSE RESPONSE; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; ESTROGEN ACTIVITY; FLUORESCENCE ANGIOGRAPHY; FOOD AND DRUG ADMINISTRATION; HUMAN; INJECTION SITE REACTION; LASER COAGULATION; MONOTHERAPY; NONHUMAN; OXYGEN TOXICITY; PERFORATING EYE INJURY; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PRIORITY JOURNAL; RABBIT; RETINA BLOOD VESSEL; RETINA MACULA AGE RELATED DEGENERATION; RETROLENTAL FIBROPLASIA; REVIEW; SUBRETINAL NEOVASCULARIZATION; THERAPY EFFECT; TREATMENT OUTCOME; TUMOR VOLUME; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; CHOROIDAL NEOVASCULARIZATION; HUMANS; MACULAR DEGENERATION; PREGNADIENEDIOLS; TREATMENT OUTCOME;

EID: 33748774396     PISSN: 08961549     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ohc.2006.05.006     Document Type: Review

References (31)

1. Current Population Reports. Population projections of the United States by age, sex, race, and Hispanic origin: 1995-2050. Series P25-1130 (1996), United States Bureau of the Census, Washington
2. Macular Photocoagulation Study Group. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol 104 (1986) 503-512
3. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization: five-year results from randomized clinical trials. Arch Ophthalmol 112 (1994) 500-509
4. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators, and Verteporfin in Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 22 (2002) 6-18
5. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin - TAP report 1. Arch Ophthalmol 117 (1999) 1329-1345
6. Singerman L.J. Eyetech Study Group. Anti-VEGF therapy for subfoveal choroidal neovascularization to age-related macular degeneration: phase IB results. Invest Ophthalmol Vis Sci 43 (2002) S2908
7. www.agingeye.net/mainnews/Lucentis. Accessed July 5, 2006.
8. Crum R., Szabo S., and Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 230 (1985) 1375-1378
9. Ciulla T.A., Walker J.D., Fong D.S., et al. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol 15 (2004) 211-220
10. Wang Y.S., Friedrichs U., Eichler W., et al. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol 240 (2002) 42-48
11. Fotsis T., Zhang Y., Pepper M.S., et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth. Nature 368 (1994) 237-239
12. Ciulla T.A., Criswell M.H., Danis R.P., et al. Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina 22 (2003) 808-814
13. Genaidy M., Kazi A.A., Peyman G.A., et al. Effect of squalamine on iris neovascularization in monkeys. Retina 22 (2002) 772-778
14. Li W.W., Casey R., Gonzales E.M., et al. Angiostatic steroids potentiated by sulfated cyclodextrins inhibit corneal neovascularization. Invest Ophthalmol Vis Sci 32 (1991) 2898-2905
15. Prioa A.D., Hirakata A., McInnes J.S., et al. The effect of angiostatic steroids and beta-cyclodextrin tetradecasulfate on corneal neovascularization in the rat. Exp Eye Res 57 (1993) 693-698
16. BenEzra D., Briffin B.W., Maftzir G., et al. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci 38 (1997) 1954-1962
17. Phelps D.L., and Rosenbaum A.L. Vitamin E in kitten oxygen-induced retinopathy. II. Blockage of vitreal neovascularization. Arch Ophthalmol 97 (1979) 1522-1526
18. Penn J.S., Henry M.M., and Tolman B.L. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res 36 (1994) 724-731
19. Smith L.E., Wesolowski E., McLellan A., et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35 (1994) 101-111
20. Penn J.S., Rajaratnam V.S., Collier R.J., et al. The effect of an angiostatic steroid on neovascularization in a rat model of prematurity. Invest Ophthalmol Vis Sci 42 (2001) 283-290
21. Bingaman D.P., Liu C., and Landers R. Local delivery of anecortave acetate inhibits laser-induced choroidal neovascularization (CNV) in the mouse. Invest Ophthalmol Vis Sci 45 (2004) S180
22. Clark A.F., Mellon J., Li X.Y., et al. Inhibition of ocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest Ophthalmol Vis Sci 40 (1999) 2158-2162
23. Clark A.F. AL-3789: a novel ophthalmic angiostatic steroid. Exp Opin Invest Drugs 6 (1997) 1867-1877
24. AG Mice. Invest Ophthalmol Vis Sci 47 (2006) 1264-1268
25. DeFaller J.M., and Clark A.F. A new pharmacological treatment for angiogenesis. In: Taylor H.R. (Ed). Pterygium (2000), Kugler Publications, The Hague, The Netherlands 159-181
26. Yang R., McCollum G.W., Bingaman D.P., et al. Inhibition of VEGF-induced endothelial cell proliferation and differentiation by steroidal and non-steroidal COX inhibitors with variable COX-1/COX-2 selectivity. Invest Ophthalmol Vis Sci 45 (2004) E-Abstract 1914
27. Liu C., Gu X., Wang W., et al. Local delivery of anecortave acetate inhibits the expression of retinal IGF-1/IGF-1 receptor in the rat OIR model. Invest Ophthalmol Vis Sci 46 (2005) E-Abstract 4135
28. Dahlin D.C., Trawick D., Zilliox P., et al. Design of a specialized cannula for posterior juxtascleral delivery of anecortave acetate tot the retina for treatment of CNV associated with age-related macular degeneration (AMD). Invest Ophthalmol Vis Sci 44 (2003) E-Abstract 5036
29. The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 23 (2003) 14-23
30. The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration (AMD): 12 month clinical outcomes. Ophthalmology 110 (2003) 2372-2383
31. Slakter J.S., Bochow T., D'Amico D.J., et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 113 (2006) 3-13